Drugs with dual-hormone action gain attention in diabetes field

Engineered peptide drugs that simultaneously target two hormone receptors have historically attracted interest among scientists hoping to create new treatments for diabetes. Now, many in the field seem buoyed by new data from a class of diabetes medicines designed to mimic gastrointestinal hormones...

Full description

Saved in:
Bibliographic Details
Published inNature medicine Vol. 19; no. 12; p. 1549
Main Author Hackethal, Veronica
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.12.2013
Nature Publishing Group
Subjects
631/154/51
692/308
692/699/2743/137
Biomedicine
Biomimetic Materials - therapeutic use
Cancer Research
Care and treatment
Diabetes
Diabetes Mellitus - drug therapy
Endocrinology - methods
Endocrinology - trends
Gastrointestinal Agents - therapeutic use
Gastrointestinal hormones
Genetic engineering
Glucagon-Like Peptide-1 Receptor
Hormone receptors
Hormones
Humans
Hypoglycemic Agents - therapeutic use
Incretins - therapeutic use
Infectious Diseases
Metabolic Diseases
Molecular Medicine
Neurosciences
news
Pancreatic beta cells
Peptides
Pharmaceuticals
Physiological aspects
Receptors, Glucagon - agonists
Studies
United States
Online AccessGet full text

Cover

More Information
Summary:Engineered peptide drugs that simultaneously target two hormone receptors have historically attracted interest among scientists hoping to create new treatments for diabetes. Now, many in the field seem buoyed by new data from a class of diabetes medicines designed to mimic gastrointestinal hormones called incretins, which stimulate insulin release from pancreatic beta cells.
Bibliography:SourceType-Other Sources-1
ObjectType-News-1
content type line 66
ISSN:1078-8956
1546-170X
DOI:10.1038/nm1213-1549